





Identification of LY3522348: A Highly Selective and Orally Efficacious Ketohexokinase (KHK) Inhibitor

Timothy B. Durham, Ph.D., *Executive Director, Discovery Chemistry Research, Eli Lilly and Company, Indianapolis, IN*

Ketohexokinase (KHK) is the first step in fructose metabolism. Inhibitors of KHK have potential as therapies for diabetes, non-alcoholic hepatic steatosis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, and diabetic kidney disease. The medicinal chemistry program which culminated in the identification of clinical candidate LY3522348 will be shared.



Durham T. B.; Hao, J.; Spinazze, P.; Stack, D. R.; Toth, J. L.; Massey, S.; Mbofana, C. T.; Johnston, R. D.; Lineswala, J. P.; Wroblewski, A.; Mínguez, J. M.; Perez, C.; Smith, D. L.; Lamar, J.; Leon, R.; Corkins, C.; Durbin, J.; Tung, F.; Guo, S.; Linder, R. J.; Yumibe, N.; Wang, W.; MacKrell, J.; Antonellis, M.; Mascaro, B. Identification of LY3522348: A Highly Selective and Orally Efficacious Ketohexokinase Inhibitor. *J. Med. Chem.* **2023**, 66, 15960-15976. doi: 10.1021/acs.jmedchem.3c01410.